drug
use
today
target
protein
includ
receptor
enzym
transport
protein
tradit
smallmolecul
drug
target
bind
site
modifi
protein
function
gener
act
agonist
antagonist
modern
altern
approach
modifi
target
protein
concentr
exampl
reduc
translat
complementari
rna
sequenc
activ
protein
degrad
pathway
believ
wide
varieti
current
futur
protein
target
downmodul
mechan
previous
recogn
medicin
chemist
inhibit
cotransl
transloc
across
membran
endoplasm
reticulum
er
cellsurfac
secret
human
protein
produc
proteinencod
gene
transport
cell
membran
secretori
pathway
highli
conserv
eukaryot
way
back
evolutionari
chain
bacteria
protein
human
translat
ribosom
surfac
er
transport
cell
membran
via
golgi
apparatu
mammal
protein
contain
amino
acid
gener
target
er
membran
translat
enter
interior
lumen
er
cross
membran
elong
process
known
cotransl
transloc
success
transloc
protein
import
proper
function
cell
defect
protein
transloc
link
mani
diseas
includ
cancer
numer
hereditari
diseas
drug
target
nascent
protein
chain
cotransl
transloc
potenti
reduc
express
mani
cellsurfac
secretori
protein
import
therapeut
target
type
type
ii
transmembran
receptor
gprotein
coupl
receptor
gcpr
inflammatori
cytokin
etc
addit
drug
treat
human
condit
aris
protein
overexpress
malfunct
potenti
opportun
new
antiinfect
drug
mani
viral
protein
hepat
c
polyprotein
host
protein
requir
life
cycl
virus
use
pathway
bacteri
toxin
poreform
protein
express
similar
process
except
smaller
protein
cross
er
membran
posttransl
nascent
membran
protein
target
cotransl
er
membran
channel
translocon
mean
signal
sequenc
signal
peptid
sp
mammalian
cell
smaller
protein
bear
sp
larger
protein
poorli
function
sp
pull
channel
chaperon
er
lumen
bip
heat
shock
famili
protein
type
transmembran
protein
hiv
entri
receptor
cluster
differenti
sp
first
amino
acid
nterminu
nascent
chain
preprotein
gprotein
coupl
receptor
gpcr
target
drug
market
ntermin
signal
peptid
remaind
first
transmembran
domain
serv
signal
sequenc
target
translocon
dynam
mechan
cotransl
transloc
protein
ntermin
sp
complet
elucid
molecular
level
model
shown
fig
base
previous
report
model
cryoem
structur
ribosomenasc
chain
complex
rnc
studi
describ
structur
translocon
univers
conserv
sp
wide
varieti
primari
structur
specif
everi
protein
differ
protein
differ
speci
sp
central
hydrophob
domain
consist
least
six
nonhydrophil
amino
acid
residu
form
two
turn
label
h
fig
cation
ntermin
domain
label
n
fig
ctermin
segment
h
region
cleavag
site
nterminu
matur
protein
label
c
fig
eukaryot
main
compon
heterotrimer
translocon
term
consist
ten
transmembran
adopt
shape
hourglass
rest
state
leakag
calcium
constitu
lumen
prevent
residu
form
central
pore
ring
short
termin
serv
plug
protein
translat
begin
cytosol
emerg
sp
ribosom
bound
signal
recognit
particl
srp
temporarili
arrest
slow
translat
srp
bind
srp
receptor
sr
er
membran
ribosom
nascent
protein
chain
rnc
transfer
translocon
convert
prime
state
key
featur
translocon
later
gate
partial
open
rnc
bind
expos
hydrophob
pocket
fig
step
probe
orient
sp
translocon
rnc
use
translat
arrest
glycosyl
tag
ad
n
terminu
glycosyl
show
n
terminu
initi
face
er
lumen
studi
suggest
sp
transmembran
signal
sequenc
type
ii
signal
anchor
protein
initi
bind
translocon
headfirst
n
termini
face
er
lumen
translat
push
nascent
chain
deeper
translocon
sp
appar
flipturn
reorient
n
terminu
face
cytosol
fig
step
sp
appar
move
fulli
later
gate
make
room
elong
chain
pass
channel
er
lumen
sp
cleav
signal
peptidas
spase
lumin
surfac
er
membran
chain
elong
continu
type
transmembran
protein
hydrophob
transmembran
segment
produc
bind
later
gate
pass
er
membran
fig
step
final
protein
releas
mrna
stop
codon
reach
ribosom
dissoci
er
fig
step
effici
protein
transloc
vari
consider
protein
protein
protein
appar
transloc
without
help
chaperon
forc
chain
elong
translat
push
nascent
protein
translocon
certain
specif
structur
factor
known
facilit
transloc
includ
basic
residu
n
region
sp
hydrophob
residu
especi
leucin
h
domain
posit
charg
n
domain
facilit
cytosol
orient
shown
step
fig
hydrophob
h
domain
favor
insert
later
gate
gate
appar
make
room
passag
downstream
residu
channel
human
prion
preprotein
sp
minim
posit
charg
n
region
weakli
hydrophob
h
region
undergo
bipassist
cotransl
transloc
ntocytosol
orient
prion
protein
appar
destabil
four
posit
charg
residu
n
terminu
matur
domain
chaperon
assist
appar
requir
transloc
protein
effect
push
translocon
forc
translat
elong
either
enter
channel
posttransl
easili
achiev
requir
ntocytosol
orient
bip
atpas
role
facilit
transloc
subset
protein
make
potenti
drug
target
number
hereditari
diseas
suppress
protein
express
associ
singlesit
mutat
introduc
polar
amino
acid
side
chain
sp
h
region
preprotein
mani
mutat
replac
leucin
arginin
includ
follow
seven
disord
classic
ehlersdanlo
syndrom
criglernajjar
diseas
hereditari
angioedema
juvenil
hyperuricem
neuropathi
hereditari
hypotrichosi
simplex
narcolepsi
perman
neonat
diabet
believ
signal
peptidopathi
may
introduc
saltbridg
interact
downstream
residu
nascent
chain
disord
may
possibl
develop
smallmolecul
drug
inhibit
interact
facilit
normal
transloc
sp
cleavag
interest
sp
mani
protein
h
region
contain
polar
uncharg
amino
acid
residu
asparagin
glutamin
serin
threonin
tyrosin
tryptophan
even
contain
charg
residu
aspart
glutam
lysin
arginin
mani
contain
cystein
potenti
form
coval
bond
result
neutral
mutat
rel
slow
rate
evolut
sp
variabl
effici
suggest
nt
sp
h
domain
compos
sole
hydrophob
residu
leucin
isoleucin
valin
phenylalanin
propos
structur
sp
evolutionarili
match
matur
domain
facilit
effici
transloc
also
recogn
maximum
transloc
effici
alway
optim
sp
use
cell
control
effici
protein
compartment
attenu
protein
transloc
respons
er
stress
transloc
step
serv
checkpoint
protein
regul
nonoptim
hresidu
may
select
reduc
effici
express
protein
interest
case
luten
hormon
receptor
lhr
common
human
mutat
inslqlhr
introduc
two
addit
amino
acid
h
region
lhr
preprotein
increas
effici
transloc
lhr
express
women
mutat
statist
correl
shorten
diseasefre
breast
cancer
surviv
rate
polar
residu
h
region
may
benefici
effect
regul
express
mani
protein
potenti
serv
handl
sptarget
drug
number
smallmolecul
exotoxin
virul
factor
plant
secondari
metabolit
identifi
inhibit
protein
cotransl
transloc
nonselect
bind
block
translocon
compound
includ
apratoxin
eeyerestatin
exotoxin
mycolacton
ipomoeassin
f
coibamid
inhibit
express
mani
protein
gener
produc
toxic
pharmacokinet
evalu
mycolacton
subcutan
analges
recent
report
author
found
mice
analges
effect
mycolacton
depend
angiotensin
ii
receptor
r
relat
previous
report
suppress
inflamm
observ
consist
expect
mycolacton
inhibit
transloc
angiotensin
precursor
protein
angiotensinogen
express
sp
nterminu
preprotein
henc
angiotensinogen
sp
could
becom
target
develop
select
analges
drug
well
antihypertens
agent
cytotox
effect
substratenonselect
transloc
inhibitor
also
suggest
translocon
target
anticanc
drug
interestingli
translocon
mutat
channelopathi
impair
protein
transloc
mani
associ
certain
diseas
diabet
conceiv
small
molecul
act
transloc
facilit
could
use
treatment
diseas
first
report
substrateselect
inhibitor
protein
cotransl
transloc
cycloheptadepsipeptid
fungal
metabolit
analog
cotransin
fig
photoaffin
label
resist
mutat
studi
shown
cycloheptadepsipeptid
primarili
bind
subunit
translocon
potent
inhibit
transloc
certain
preprotein
spselect
manner
two
protein
target
cyclodepsipeptid
vascular
cell
adhes
molecul
vascular
endotheli
growth
factor
vegf
mutagenesi
studi
sp
ntermin
matur
domain
protein
perform
show
import
specif
amino
acid
h
c
domain
cyclodecadepsipeptid
name
decatransin
also
report
inhibit
protein
cotransl
transloc
similar
select
profil
resist
mutat
occur
similar
locat
also
interest
cyclodecadepsipeptid
ionophor
antibiot
valinomycin
report
inhibit
transloc
hamster
human
prion
protein
valinomycin
known
downregul
bip
assist
transloc
prion
preprotein
suggest
hamster
prion
nascent
chain
might
requir
assist
bip
human
variant
hand
valinomycin
decatransin
similar
size
hydrophob
suggest
may
bind
translocon
similar
manner
leav
reason
substrat
select
unclear
cotransin
mechanist
classifi
gate
inhibitor
bind
translocon
appar
block
access
nascent
protein
chain
later
gate
hydrophob
structur
suggest
may
compet
h
domain
nascent
chain
sp
bind
later
gate
rough
correl
sensit
inhibitori
effect
sp
hydrophob
observ
mechanist
model
report
cotransin
bind
alloster
prevent
later
gate
sp
transmembran
domain
tmd
increas
hydrophob
helic
propens
overrid
cotransinimpos
block
hand
hregion
conform
consensu
motif
sensit
signal
sequenc
cotransin
identifi
report
specif
combin
certain
amino
acid
import
rather
length
hydrophob
signal
sequenc
nonselect
transloc
inhibitor
apratoxin
macrocycl
tetrapeptid
also
act
gate
inhibitor
resist
mutat
occur
similar
area
cotransin
decatransin
propos
compound
bind
act
similar
ident
manner
macrocycl
triamin
cyclotriazadisulfonamid
cada
small
molecul
inhibit
replic
variou
strain
human
immunodefici
viru
hiv
simian
immunodefici
viru
siv
select
downmodul
express
cellsurfac
cluster
differenti
type
integr
transmembran
glycoprotein
express
immun
cell
primari
receptor
requir
hiv
enter
host
cell
cada
compound
radic
differ
convent
antihiv
agent
viral
target
highli
suscept
onset
resist
mutat
select
mechan
cada
compound
target
cellular
machineri
express
essenti
receptor
hiv
entri
henc
quit
difficult
gener
cadaresist
viru
vitro
result
strain
rel
poor
infect
suscept
neutral
antibodi
cada
low
cytotox
shown
select
downmodul
without
affect
express
surfac
protein
examin
tcell
avail
evid
indic
cada
act
cotransl
transloc
inhibitor
direct
interact
human
sp
vide
infra
proteom
survey
use
high
throughput
monoclon
antibodi
panelbas
immunoblot
assay
cellular
signal
protein
reveal
sortilin
second
substrat
cada
screen
base
panel
monoclon
antibodi
cover
wide
array
intracellular
pathway
doserespons
curv
shown
fig
cadainduc
downmodul
human
construct
consist
sortilin
sp
green
fluoresc
protein
gfp
fuse
cterminu
absolut
ic
concentr
protein
decreas
valu
sortilin
respect
absolut
ic
valu
clinic
relev
inflect
point
give
rel
ic
import
mechan
action
calcul
concentr
give
maximum
effect
observ
drug
result
rel
ic
valu
sortilin
respect
ideal
condit
rel
ic
valu
equal
dissoci
constant
drugtarget
complex
henc
cada
appear
bind
almost
strongli
sortilin
sp
sp
yet
maximum
downmodul
sortilin
decreas
sortilin
recent
identifi
potenti
drug
target
mani
disord
includ
frontotempor
lobar
degener
autism
alzheim
diseas
atherosclerosi
breast
cancer
last
therapeut
applic
involv
cancer
stem
cell
csc
subpopul
cancer
cell
similar
properti
normal
stem
cell
abil
selfrenew
differenti
form
heterogen
cancer
cell
csc
perpetu
tumor
even
treatment
lead
tumor
aggress
heterogen
caus
resist
anticanc
therapi
progranulin
identifi
secret
csc
modul
contribut
breast
cancer
progress
progranulin
role
tumor
growth
therapyinduc
resist
variou
cancer
type
associ
bind
neuron
receptor
sortilin
interest
downmodul
sortilin
breast
cancer
treatment
increas
associ
breast
cancer
metastat
potenti
furthermor
sortilin
highli
express
breast
cancer
cell
line
compar
nontumorigen
epitheli
cell
sortilin
bind
progranulin
regul
could
benefici
halt
breast
cancer
progress
propos
moa
downmodul
cellsurfac
cada
compound
shown
fig
cada
effect
product
mrna
target
rnc
er
membran
absenc
er
microsom
cada
effect
synthesi
vitro
presenc
er
microsom
cada
prevent
transloc
across
er
membran
rnc
bear
ntermin
glycosyl
tag
cada
shown
inhibit
invers
sp
block
transloc
lead
divers
cytosol
fig
step
degrad
proteolysi
current
known
whether
cadadisplac
protein
degrad
ubiquit
proteasom
system
accord
surfac
plasmon
reson
spr
studi
cada
directli
bind
sp
human
probabl
gener
primat
mous
less
homolog
human
sp
postul
cada
bind
sp
fold
conform
stabil
otherwis
transitori
state
invers
process
shown
fig
cada
specif
select
cotransl
transloc
inhibitor
proven
primarili
target
sp
deduc
physicochem
properti
cada
bind
site
sp
carri
number
structureact
relationship
sar
studi
quantit
sar
studi
show
import
hydrophob
tail
group
downmodul
antihiv
potenc
also
systemat
vari
substitu
one
side
arm
determin
influenc
posit
electron
donatingwithdraw
abil
potenc
seen
fig
replac
paramethoxi
group
dimethylamino
enhanc
potenc
benzyl
tail
seri
move
paradimethylamino
meta
posit
decreas
potenc
paranitro
analog
low
potenc
move
nitro
meta
ortho
posit
restor
potenc
effect
understood
consid
electron
densiti
alon
red
electron
rich
blue
electron
poor
fig
calcul
dipol
moment
n
ndimethylarenesulfonamid
model
side
arm
found
linear
correl
pic
valu
downmodul
compon
dipol
moment
plane
benzen
ring
model
compound
fig
inset
ic
valu
relat
dissoci
constant
drugtarget
complex
result
indic
interact
side
arm
dipol
sp
major
determin
bind
energi
requir
hydrophob
tail
group
potenc
cada
compound
practic
concern
potent
downmodul
sortilin
poorli
bioavail
low
water
solubl
fortun
requir
hydrophob
extend
one
arenesulfonamd
side
arm
potent
cada
compound
prepar
better
solubl
due
greater
polar
side
arm
region
synthet
studi
coupl
address
key
amino
acid
residu
human
sp
interact
cada
thorough
alanin
scan
mutagenesi
studi
conduct
amino
acid
ntermin
region
preprotein
consist
residu
sp
plu
first
residu
matur
protein
previous
determin
essenti
cada
sensit
effect
residu
cada
sensit
investig
analyz
two
differ
protein
structur
full
length
fl
express
cell
surfac
yellow
fluoresc
protein
yfp
carri
amino
acid
residu
nterminu
follow
first
ntermin
amino
acid
human
sortilin
put
n
h
c
domain
shown
red
green
blue
respect
propos
critic
glutamin
residu
h
domain
shown
violet
analysi
hydrophob
region
reveal
four
key
amino
acid
residu
preprotein
contribut
cada
sensit
mutat
largest
effect
made
cada
potenc
immeasur
fl
yfp
construct
correl
side
arm
dipol
moment
potenc
describ
propos
cada
compound
recogn
dipoledipol
interact
replac
alanin
second
largest
effect
reduc
cada
potenc
attribut
either
secondari
interact
cada
effect
decreas
posit
charg
near
n
region
sp
also
replac
alanin
result
greatli
decreas
sensit
cada
especi
yfp
construct
convert
glycin
fulli
restor
cada
sensit
consist
residu
form
hairpin
turn
model
prolin
glycin
known
helix
termin
exchang
valin
residu
result
decreas
sensit
cada
attribut
increas
hydrophob
gener
trend
observ
lower
hydrophob
h
region
increas
sensit
cada
final
replac
alanin
also
significantli
decreas
cada
potenc
attribut
decreas
posit
charg
n
terminu
matur
domain
compar
sp
sortilin
sp
see
interest
similar
first
polar
glutamin
residu
h
region
consist
hypothesi
import
bind
dipoledipol
interact
cada
sp
note
rel
ic
valu
suggest
cada
bind
sortilin
similar
affin
also
sp
sortilin
h
domain
termin
prolin
actual
two
prolin
case
sortilin
turn
end
hregion
may
import
stabil
fold
structur
drugtarget
complex
keep
cleavag
site
away
spase
activ
site
lumin
side
er
membran
key
differ
sp
n
domain
sortilin
twice
long
may
explain
lower
efficaci
transloc
inhibit
cada
sortilin
cleavag
site
may
statist
posit
much
closer
spase
activ
site
emerg
specul
far
sp
druggabl
must
one
polar
otherwis
recogniz
amino
acid
h
domain
highest
degre
secondari
structur
nascent
chain
one
prolin
glycin
residu
termin
h
region
polar
group
h
region
may
resid
hydrophob
environ
later
gate
enhanc
bind
energi
polar
interact
includ
dipoledipol
interact
hydrogen
bond
salt
bridg
discoveri
cada
abil
decreas
express
specif
protein
spdepend
manner
open
door
possibl
signal
peptid
may
becom
valid
target
drug
design
certainli
challeng
specif
biomolecular
structur
target
cada
compound
fleet
exist
dynam
process
number
factor
suggest
mani
nascent
protein
could
select
target
mechan
sp
protein
uniqu
mani
contain
residu
h
region
might
target
ionic
hydrogen
bond
dipolar
coval
interact
alreadi
familiar
medicin
chemist
cotransl
transloc
process
fallibl
handl
drug
bind
may
introduc
evolutionarili
adapt
modul
protein
express
discov
new
drug
inhibit
cotransl
transloc
therapeut
interest
protein
specul
may
alreadi
drug
poorli
character
mechan
bind
sp
believ
one
exampl
may
atyp
antidepress
tianeptin
select
serotonin
reuptak
inhibitor
despit
tricycl
structur
studi
found
tianeptin
receptor
agonist
other
show
recent
inhibit
neuron
inflamm
suppress
tolllik
receptor
pathway
nonplanar
sulfonamid
aromat
benzen
ring
could
bind
sp
hregion
van
der
waal
interact
propos
cada
compound
tianeptin
might
downmodul
receptor
cytokin
inflamm
pathway
inhibit
cotransl
transloc
across
er
membran
search
develop
new
spbind
drug
suggest
focus
protein
recogn
therapeut
potenti
sp
contain
potenti
recogniz
residu
h
domain
includ
asparagin
aspart
cystein
glutam
glutamin
histidin
lysin
methionin
serin
threonin
tryptophan
tyrosin
follow
list
protein
potenti
druggabl
sp
includ
relev
therapeut
applic
parenthes
angiotensinconvert
enzym
sarscov
hemagglutinin
influenza
martx
protein
cholera
plasmepsin
x
malaria
hiv
bal
anthrax
integrin
alphaiib
anticoagul
fibrinogen
alpha
chain
anticoagul
sclerostin
osteoporosi
alzheim
amyloid
beta
alzheim
complement
rheumatoid
arthriti
gmcsf
rheumatoid
arthriti
thyroglobulin
hyperthyroid
myostatin
muscl
loss
growth
arrestspecif
muscl
loss
multipl
sclerosi
glycoprotein
bgb
cytomegaloviru
kirrel
autismintellectu
disabl
candidialysin
candida
albican
toxic
cadherin
autism
thyroid
stimul
hormon
receptortshr
grave
diseas
tolllik
receptor
anxieti
neurodegen
diseas
stroke
recoveri
structur
protein
refer
relat
disord
may
found
uniprot
websit
http
wwwuniprotorguniprot
search
author
declar
known
compet
financi
interest
person
relationship
could
appear
influenc
work
report
public
